.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for addition of patients with MASLD and dimension of liver results in cardio-- kidney-- metabolic trials, when records suggest mechanistically probable advantages and professional protection-- and outlines points to consider for trial layout as well as regulative commendation.